Current Medicinal Chemistry
-
- Visão geral
-
- Metrics
-
- Identidade
-
- Ver todos
-
Visão geral
Qualis
código do país
tipo
publicação venue de
-
Administration of inhibitory molecules through nanoparticles in breast cancer therapy.
30:123.
2023-01-01
-
Assessing the Therapeutic and Toxicological Profile of Novel AcetylcholinesteraseReactivators: Value of In Silico And In Vitro Data.
30:4149-4166.
2023-01-01
-
Biomarkers in Hypertension and Hypertension-related Disorders.
30:3846-3879.
2023-01-01
-
C-KIT Receptor Inhibition as a Promising Approach to Design Anticancer Drugs..
30:01-03.
2023-01-01
-
Chalcone Derivatives as Antibacterial Agents: An Updated Overview.
30:1.
2023-01-01
-
Congenital Solitary Functioning Kidney: A Review.
30:203-219.
2023-01-01
-
Drug delivery systems based in microneedles for dermatological diseases and aesthetic enhancement.
30:1-25.
2023-01-01
-
Effectiveness in vivo and in vitro of Polymeric Nanoparticles as a Drug Release System in the Treatment of Leishmaniasis.
30:1-14.
2023-01-01
-
Entering the sugar rush era: revisiting the antihyperglycemic activities of biguanides after a century of metformin discovery.
30:2542-2561.
2023-01-01
-
Exploring Scoring Function Space: Developing Computational Models for Drug Discovery.
30:1-17.
2023-01-01
-
In Silico Studies on Natural Products and Derivatives Against Different Types of Cancer.
30:1-9.
2023-01-01
-
Medicinal (Radio)Chemistry: Building Radiopharmaceuticals for the Future.
31:1.
2023-01-01
-
New molecules of importance in the prevention and treatment of acne: A systematic patent review (2016-2020).
31:1.
2023-01-01
-
Novel Biomarkers for Posterior Urethral Valve.
30:1712-1735.
2023-01-01
-
Novel Synthesized Tyrosinase Inhibitors: A Systematic Patent Review (2012-Present).
30:1-10.
2023-01-01
-
PBPK modeling as an alternative method of extrapolation interspecies that reduce the use of animals: a systematic review....
30:1.
2023-01-01
-
Recent Advances on the Antimicrobial Activities of Schiff Bases and their Metal Complexes: An Updated Overview.
30:00.
2023-01-01
-
SARS-CoV-2 Infection, Inflammation, Immunonutrition, and Pathogenesisof COVID-19.
30:4390-4408.
2023-01-01
-
Thiazole, isatin and phthalimide derivatives tested in vivo against cancer models: a literature review of the last six years.
30:02-1875-533X.
2023-01-01
-
Treatment of Alzheimer's Disease: Contemporary Perspectivesin Medicinal Chemistry.
30:667-668.
2023-01-01
-
A revision of polymeric nanoparticles as a strategy to improve the biological activity of melatonin..
29:1-10.
2022-01-01
-
Acute Post-Streptococcal Glomerulonephritis In Children: A Comprehensive Review.
29:5543-5559.
2022-01-01
-
Alamandine Induces Neuroprotection in Ischemic Stroke Models.
29:1-1.
2022-01-01
-
Anticholinesterase agents for Alzheimer's Disease treatment: an updated overview..
29:x-x.
2022-01-01
-
Antitumor and antiparasitic activity of antimicrobial peptides derived from snake venom: a systematic review approach.
29:1-10.
2022-01-01
-
Biomarkers In Hypertension And Hypertension-Related Disorders.
29:02--.
2022-01-01
-
Chalcogenium-AZT derivatives: a plausible strategy to tackle the RT-inhibitors-related oxidative stress while maintaining their anti-HIV properties.
29:1-2449.
2022-01-01
-
Chemotherapy and anticancer drugs adjustment in obesity: a narrative review..
29:1-1028.
2022-01-01
-
Chronic Kidney Disease-Mineral Bone Disease biomarkers in kidney transplant patients.
29:5230-5253.
2022-01-01
-
Cinnamaldehyde for the Treatment of Microbial Infections: Evidence Obtained from Experimental Models.
29:1-3526.
2022-01-01
-
Computer-Aided Drug Design of Anti-inflammatory Agents Targeting Microsomal Prostaglandin E2 Synthase-1 (mPGES-1)..
29:00-00.
2022-01-01
-
Cucurbitacins and the Immune System: Update in Research on Anti-inflammatory, Antioxidant, and Immunomodulatory Mechanisms.
29:3774-3789.
2022-01-01
-
Current applications and benefits of polymeric nanocarriers for management of skin disorders.
29:1-10.
2022-01-01
-
DYRK1A inhibitors and perspectives for the treatment of Alzheimer's disease.
29:1-49.
2022-01-01
-
Detection of Prostate Cancer Biomarker PCA3 by using Aptasensors.
29:1.
2022-01-01
-
EDITORIAL Recent Natural Anticancer Agents.
29:164-165.
2022-01-01
-
Editorial - Entry Inhibitors of RNA Viruses.
29:609-611.
2022-01-01
-
Entering the sugar rush era: revisiting the antihyperglycemic activities of biguanides after a century of metformin discovery.
1:1-14.
2022-01-01
-
Hesperidin Methyl Chalcone: An Emerging Compound for the Treatment of Inflammation and Pain.
29:1-603.
2022-01-01
-
Imaging markers of neurologic damage in COVID-19: a systematic review.
29:1-1106.
2022-01-01
-
Metallic Nanoparticles: A New Frontier in the Fight Against Leishmaniasis.
29:1-1.
2022-01-01
-
Mutual effects of free and nanoencapsulated phenolic compounds on human microbiota.
29:3160-3178.
2022-01-01
-
Nephrogenesis, Renal Function, and Biomarkers in Preterm Newborns.
29:4097-4112.
2022-01-01
-
Neuropharmacology of Organoselenium Compounds in Mental Disorders and Degenerative Diseases.
29:2357-2395.
2022-01-01
-
Outlining the molecules tested in vivo for Chagas disease, Malaria, and Schistosomiasis over the last six years - a literature review focused on new synthetic drug identities and repurposing strategies.
29:01-45.
2022-01-01
-
Oxadiazole Derivatives as Anticancer and Immunomodulatory Agents: A Systematic Review.
29:1-14.
2022-01-01
-
Polymeric systems for colon-specific Mesalazine delivery in the intestinal bowel diseases management.
29:1-1367.
2022-01-01
-
Potential Application of Cephalosporins Carried in Organic or Inorganic Nanosystems Against Gram-negative Pathogens.
29:01-5229.
2022-01-01
-
The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: AReview on Vaccine Mechanisms, Results of Clinical Trials, VaccinalCoverage and Interactions with Novel Variants.
29:2673-2690.
2022-01-01
-
The role of alternative toxicological trials in drug discovery programs: The case of Caenorhabditis elegans and other methods.
29:5270-5270.
2022-01-01
-
Topical Application of Ascorbic Acid and its Derivatives: a Review Considering Clinical Trials.
29:01-16.
2022-01-01
-
A review of properties, delivery systems and analytical methods for the characterization of monomeric glycoprotein transferrin.
51:399-410.
2021-01-01
-
Advances in Sickle Cell Disease Treatments.
28:2008-2032.
2021-01-01
-
Alport Syndrome: a comprehensive review on genetics, pathophysiology, histology, clinical, and therapeutic perspectives.
28:5602-5624.
2021-01-01
-
An overview of the α4β1 integrin and the potential therapeutic role of its antagonists.
28:1-12.
2021-01-01
-
Antioxidant Effects of Chalcones during the Inflammatory Response: An Overall Review.
28:29.
2021-01-01
-
Antiprotozoal and anthelmintic activity of zinc oxide nanoparticles.
28:1-1.
2021-01-01
-
Application of Machine Learning Techniques for Drug Discovery.
28:7805-7807.
2021-01-01
-
Astrocytes and Inflammasome: A Possible Crosstalk in Neurological Diseases.
28:4972-4994.
2021-01-01
-
COVID-19 Related Coagulopathy: What is Known Up to Now.
28:4207-4225.
2021-01-01
-
Chalcones Acting as Inhibitors of Cholinesterases, β-Secretase and β- Amyloid Aggregation and other Targets for Alzheimer’s Disease: A Critical Review.
28:4259-4282.
2021-01-01
-
Computational Prediction of Binding Affinity for CDK2-ligand Complexes. A Protein Target for Cancer Drug Discovery.
28:1-17.
2021-01-01
-
Electrostatic Potential Energy in Protein-Drug Complexes.
28:1-17.
2021-01-01
-
Implications of VIP and PACAP in Parkinson's Disease: What do we know so far?.
28:1703-1715.
2021-01-01
-
Inhibiting the 'Undruggable' RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products.
28:1-22.
2021-01-01
-
Insight into Recent Drug Discoveries against Trypanosomatids and Plasmodium spp Parasites: New Metal-based Compounds.
28:1-2381.
2021-01-01
-
Machine Learning, Molecular Modeling, and QSAR Studies on Natural Products Against Alzheimer?s Disease.
28:1-7829.
2021-01-01
-
Mucoadhesive Nanosystems for Nose-to-Brain Drug Delivery in the Treatment of Central Nervous System Diseases.
28:---.
2021-01-01
-
Mutual effects of free and nanoencapsulated phenolic compounds on human microbiota.
28:1-3178.
2021-01-01
-
Natural Products as Potential Agents against SARS-CoV and SARSCoV- 2.
28:00-00.
2021-01-01
-
Natural Products with tandem Anti-inflammatory, Immunomodulatory and Anti-SARS-CoV/2 effects: A Drug Discovery Perspective against SARS-CoV-2.
28:2530-2564.
2021-01-01
-
New Perspectives in Drug Delivery Systems for the Treatment of Tuberculosis.
28:1-1958.
2021-01-01
-
Novel biomarkers for lupus nephritis in the ¿OMICS¿ era.
28:6011-6044.
2021-01-01
-
Novel therapeutic options for Chagas disease based on bioactive compounds from algae, bacteria, and fungi species.
28:1-1.
2021-01-01
-
Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells.
28:1-17.
2021-01-01
-
Pieces of the complex puzzle of cancer cell energy metabolism: an overview of energy metabolism and alternatives for targeted cancer therapy.
28:3514-3534.
2021-01-01
-
Potential Role of Adult Hippocampal Neurogenesis in Traumatic Brain Injury.
28:1-15.
2021-01-01
-
Protein-ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.
28:1-10.
2021-01-01
-
Recent Advancements in Liposome-Based Strategies for Effective Drug Delivery to the Brain.
28:4152-4171.
2021-01-01
-
Regulation of Protein Synthesis: an Approach to Treat Autistic Spectrum Disorder (ASD).
28:7141-7156.
2021-01-01
-
Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19.
28:4499-4530.
2021-01-01
-
Renin Angiotensin System in Central Nervous System diseases and its interaction with COVID-19.
28:5733-5787.
2021-01-01
-
Selenium-derivative compounds: a review of new perspectives in the treatment of Alzheimer?s disease.
29:1-10.
2021-01-01
-
Targeting Chikungunya Virus Entry: alternatives for new inhibitors in drug discovery.
28:---.
2021-01-01
-
The Emerging Landscapes to Drug Delivery Systems for the Treatment of Pancreatic Cancer.
28:1-5430.
2021-01-01
-
The Impact of CrystallographicData for the Development of Machine Learning Models to Predict Protein-Ligand Binding Affinity.
28:1-15.
2021-01-01
-
The Main Receptors Involved with COVID-19: a Systematic Review and Meta-analysis.
28:PMID: 33820514.
2021-01-01
-
The role of celecoxib as a potential inhibitor in the treatment of inflammatory diseases - a review.
28:1-3049.
2021-01-01
-
Virtual Screening and Molecular Docking: Discovering Novel c-KIT Inhibitors.
28:166-182.
2021-01-01
-
A Systematic Review of the Anti-inflammatory Effects of Gallium Compounds.
27:1-16.
2020-01-01
-
An Overview of the Compounds Tested In Vivo for Leishmania spp. of the Last 5 Years.
27:01-12.
2020-01-01
-
An Upcoming Approach to Alzheimer's Disease: Ethnopharmacological Potential of Plant Bioactive Molecules.
27:4344-4371.
2020-01-01
-
Biotechnological Potential of Streptomyces Siderophores as New Antibiotics.
27:1-15.
2020-01-01
-
COVID-19: innovative antiviral drugs required for long-term prevention and control of coronavirus diseases.
27:1-13.
2020-01-01
-
Chalcones Acting as Inhibitors of Cholinesterases, β-Secretase and β-Amyloid Aggregation and other Targets for Alzheimer?s Disease: A Critical Review.
28:1-24.
2020-01-01
-
Chitosan nanoparticles potentiate the in vitro and in vivo effects of curcumin and other natural compounds.
28:1-4953.
2020-01-01
-
Current anti-inflammatory therapies and the potential of secretory Phospholipase A2 inhibitors in the design of new anti-inflammatory drugs: a review of 2012 - 2018.
27:477-497.
2020-01-01
-
Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections.
27:1-0.
2020-01-01
-
Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration.
27:3623-3656.
2020-01-01
-
Highlights regarding the use of metallic nanoparticles against pathogens considered a priority by the World Health Organization..
12:1-1956.
2020-01-01
-
Immune-Based Therapies for Traumatic Brain Injury: Insights from pre-clinical studies.
27:5374-5402.
2020-01-01
-
Immunoconjugates for cancer targeting: a review of antibody-drug conjugates and antibody-functionalized nanoparticles.
27:1-15.
2020-01-01
-
Implantable Medical Devices and Tissue Engineering: An Overview of Manufacturing Processes and the Use of Polymeric Matrices for Manufacturing and Coating their Surfaces.
27:1580-1599.
2020-01-01
-
Implications of VIP and PACAP in Parkinson?s disease: what do we know so far?.
27:1-12.
2020-01-01
-
Insights into the design of inhibitors of the urease enzyme - a major target for the treatment of Helicobacter pylori infections.
27:1.
2020-01-01
-
Machine Learning-Based Scoring Functions. Development and Applications with SAnDReS..
27:1746-1756.
2020-01-01
-
Meet Our Editorial Board Member.
27:4753-4753.
2020-01-01
-
Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment.
27:1-418.
2020-01-01
-
NANOPARTICLES AS A TOOL FOR BROADENING ANTIFUNGAL ACTIVITIES.
27:1841-1873.
2020-01-01
-
Nanotechnology-based Drug Delivery Systems as Potential for Skin Application: A Review.
27:01-3248.
2020-01-01
-
Natural Products: Key Prototypes to Drug Discovery Against Neglected Diseases Caused by Trypanosomatids.
27:2133-2146.
2020-01-01
-
Neglected Diseases - New Compounds and Treatments.
27:659-661.
2020-01-01
-
Parthenolide and its Analogues: A New Potential Strategy for the Treatment of Triple-Negative Breast Tumors.
27:6628-6642.
2020-01-01
-
Pieces of the complex puzzle of cancer cell energy metabolism: an overview of energy metabolism and alternatives for targeted cancer therapy.
27:1-3534.
2020-01-01
-
Potential repurposing of drugs with anti-SARS-CoV-2 activity in preclinical trials: a systematic review.
27:01-09.
2020-01-01
-
Recent Theoretical Studies Concerning Important Tropical Infections.
27:795-834.
2020-01-01
-
Review about structure and evaluation of reactivators of Acetylcholinesterase inhibited with neurotoxic organophosphorus compounds.
27:1-21.
2020-01-01
-
Stimuli-responsive Drug Delivery Nanocarriers in the Treatment of Breast Cancer.
27:2494-2513.
2020-01-01
-
Structural Basis for Inhibition of Enoyl-[Acyl Carrier Protein] Reductase (InhA) from Mycobacterium tuberculosis.
27:745-759.
2020-01-01
-
The Close interplay of nitro-oxidative stress, advanced glycation end products and inflammation in inflammatory bowel diseases.
27:2059-2076.
2020-01-01
tem uma área de assunto
publisher
-
Bentham Science Publishers
is open access
-
False
invalid format
is in DOAJ
-
False
invalid format
Metrics
2 year mean citedness
H index
i10 index
Identidade
ISSN-L
openalex identifier
-
https://openalex.org/S33159018
International Standard Serial Number (ISSN)